It was previously reported that subject to availability of data in regions were studies were carried out, EGFR mutation frequency in patients with NSCLC/ LUAD was higher in women compared with men: Europe, 22 vs. 9%; Asia-Pacific 60 vs. 37%; Indian subcontinent, 31 vs. 23%; Africa, 48 vs. 8%; and North America 28 vs. 19% (36). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.